Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10756
Full metadata record
DC FieldValueLanguage
dc.contributor.authorO'Keefe, Graeme Jen
dc.contributor.authorSaunder, Timothy Hen
dc.contributor.authorNg, Stevenen
dc.contributor.authorAckerman, Uween
dc.contributor.authorTochon-Danguy, Henri Jen
dc.contributor.authorChan, J Gordonen
dc.contributor.authorGong, Sylvia Jen
dc.contributor.authorDyrks, Thomasen
dc.contributor.authorLindemann, Stefanieen
dc.contributor.authorHoll, Gerharden
dc.contributor.authorDinkelborg, Ludgeren
dc.contributor.authorVillemagne, Victor Len
dc.contributor.authorRowe, Christopher Cen
dc.date.accessioned2015-05-16T00:18:21Z
dc.date.available2015-05-16T00:18:21Z
dc.date.issued2009-01-21en
dc.identifier.citationJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2009; 50(2): 309-15en
dc.identifier.govdoc19164222en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10756en
dc.description.abstractBeta-amyloid (Abeta) imaging has great potential to aid in the diagnosis of Alzheimer disease and the development of therapeutics. The radiation dosimetry of Abeta radioligands may influence their application; therefore, we calculated and compared the effective doses (EDs) of 11C-PiB and a new 18F-labeled ligand, 18F-BAY94-9172.Attenuation-corrected whole-body scans were performed at 0, 15, 30, 45, and 60 min after injection of 350+/-28 MBq (mean+/-SD) of 11C-PiB in 6 subjects and at 0, 20, 60, 120, and 180 min after injection of 319+/-27 MBq of 18F-BAY94-9172 in 3 subjects. Coregistered CT was used to define volumes of interest (VOIs) on the PET images. The source organs were the brain, lungs, liver, kidneys, spleen, and vertebrae. The VOIs for the contents of the gallbladder, urinary bladder, lower large intestine, upper large intestine, and small intestine were also defined. Total activity in each organ at each time point was calculated by use of reference organ volumes. The resultant time-activity curves were fitted with constrained exponential fits, and cumulated activities were determined. A dynamic bladder voiding model was used. The OLINDA/EXM program was used to calculate the whole-body EDs from the acquired data.For 11C-PiB, the highest absorbed doses were in the gallbladder wall (44.80+/-29.30 microGy/MBq), urinary bladder wall (26.30+/-8.50 microGy/MBq), liver (19.88+/-3.58 microGy/MBq), and kidneys (12.92+/-3.37 microGy/MBq). The ED was 5.29+/-0.66 microSv/MBq. For 18F-BAY94-9172, the highest doses were also in the gallbladder wall (132.40+/-43.40 microGy/MBq), urinary bladder wall (24.77+/-7.36 microGy/MBq), and liver (39.07+/-8.31 microGy/MBq). The ED was 14.67+/-1.39 microSv/MBq.The estimated organ doses for 11C-PiB were comparable to those reported in earlier research. With the doses used in published studies (300-700 MBq), the EDs would range from 1.6 to 3.7 mSv. The ED of 18F-BAY94-9172 was 30% lower than that of 18F-FDG and, at the published dose of 300 MBq, would yield an ED of 4.4 mSv. The dosimetry of both Abeta radioligands is suitable for clinical and research applications.en
dc.language.isoenen
dc.subject.otherAgeden
dc.subject.otherAmyloid beta-Peptides.metabolismen
dc.subject.otherAniline Compounds.diagnostic use.pharmacokineticsen
dc.subject.otherBenzothiazoles.diagnostic use.pharmacokineticsen
dc.subject.otherCarbon Radioisotopes.diagnostic use.pharmacokineticsen
dc.subject.otherFemaleen
dc.subject.otherFluorine Radioisotopes.diagnostic use.pharmacokineticsen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherModels, Biologicalen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherRadiometryen
dc.subject.otherRadiopharmaceuticals.diagnostic use.pharmacokineticsen
dc.subject.otherStilbenes.diagnostic use.pharmacokineticsen
dc.subject.otherTissue Distributionen
dc.titleRadiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Nuclear Medicineen
dc.identifier.affiliationCentre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.2967/jnumed.108.055756en
dc.description.pages309-15en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/19164222en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.